Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT02983045

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

Sponsor: Bristol-Myers Squibb

Conditions Gastric Cancer HR+/HER2- Breast Cancer Melanoma Non Small Cell Lung Cancer Renal Cell Carcinoma Triple Negative Breast Cancer Urothelial Carcinoma

Interventions Dose Escalation Doublet: Combination of NKTR-214 + nivolumab Dose Expansion Doublet: Combination of NKTR-214 + nivolumab Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab

Updated 23 times since 2017 Last updated: Mar 9, 2023 Started: Dec 19, 2016 Primary completion: Apr 28, 2022 Completion: Apr 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Gastric Cancer and HR+/HER2- Breast Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 23 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

23 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jul 2022 — Apr 2023 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed

▶ Show 18 earlier versions

Jun 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Feb 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jul 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2019 — Jul 2020 [monthly]

Recruiting PHASE1_PHASE2
Nov 2018 — Dec 2019 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE1_PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Dec 2017 — Mar 2018 [monthly]

Recruiting PHASE1_PHASE2
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE1_PHASE2
Mar 2017 — Oct 2017 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Nektar Therapeutics

Data source: Nektar Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Boston, United States , Brzozów, Poland , Buffalo, United States , Denver, United States , Detroit, United States , Edegem, Belgium , Fairfax, United States , Gainesville, United States and 39 more locations